{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:33:45Z","timestamp":1794724425236,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76559-4","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:53:41Z","timestamp":1787302421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives"],"prefix":"10.1038","volume":"17","author":[{"given":"Alexander G.","family":"Raufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-8163","authenticated-orcid":false,"given":"Edridge K.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sedycias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pellicciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4392-9675","authenticated-orcid":false,"given":"Karan","family":"Luthria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9603-1263","authenticated-orcid":false,"given":"Somnath","family":"Tagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8786-2590","authenticated-orcid":false,"given":"Zachary H.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bircan","family":"Sema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Iuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Dajiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-078X","authenticated-orcid":false,"given":"Michael D.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0313-8120","authenticated-orcid":false,"given":"Beth A.","family":"Schrope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Fojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8036-1361","authenticated-orcid":false,"given":"Juan-Manuel","family":"Schvartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoanna","family":"Pumpalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-8590","authenticated-orcid":false,"given":"Ryan H.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-7678","authenticated-orcid":false,"given":"Linda","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanina","family":"Hibshoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-8369","authenticated-orcid":false,"given":"Aik Choon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2379-6702","authenticated-orcid":false,"given":"Benjamin","family":"Izar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7459-6036","authenticated-orcid":false,"given":"Gulam A.","family":"Manji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"76559_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. Ca. Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"Ca. Cancer J. Clin."},{"key":"76559_CR2","unstructured":"Pancreatic Cancer\u2014Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"76559_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"76559_CR4","doi-asserted-by":"crossref","unstructured":"Wu, E. Y. & Resnick, M. Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas. Precis. Cancer Med. 2, (2019).","DOI":"10.21037\/pcm.2019.09.03"},{"key":"76559_CR5","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. 26, 4814\u20134822 (2020).","journal-title":"Clin. Cancer Res."},{"key":"76559_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang, T., Ren, Y., Yang, P., Wang, J. & Zhou, H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).","journal-title":"Cell Death Dis."},{"key":"76559_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1104-x","volume":"9","author":"L Wei","year":"2018","unstructured":"Wei, L. et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9, 1065 (2018).","journal-title":"Cell Death Dis."},{"key":"76559_CR8","doi-asserted-by":"publisher","first-page":"62006","DOI":"10.18632\/oncotarget.11330","volume":"7","author":"J-C Guo","year":"2016","unstructured":"Guo, J.-C. et al. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Oncotarget 7, 62006\u201362018 (2016).","journal-title":"Oncotarget"},{"key":"76559_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/bjc.2017.134","volume":"117","author":"H Samarendra","year":"2017","unstructured":"Samarendra, H. et al. A meta-analysis of CXCL12 expression for cancer prognosis. Br. J. Cancer 117, 124\u2013135 (2017).","journal-title":"Br. J. Cancer"},{"key":"76559_CR10","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1055-9965.EPI-10-0405","volume":"19","author":"JJ Liang","year":"2010","unstructured":"Liang, J. J. et al. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 19, 2598\u20132604 (2010).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"76559_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ijrobp.2014.03.034","volume":"89","author":"TS Hong","year":"2014","unstructured":"Hong, T. S. et al. A phase 1\/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 89, 830\u2013838 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"76559_CR12","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76559_CR13","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","volume":"117","author":"D Biasci","year":"2020","unstructured":"Biasci, D. et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc. Natl. Acad. Sci. USA 117, 28960\u201328970 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76559_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119463119","volume":"119","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. Proc. Natl. Acad. Sci. USA 119, e2119463119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76559_CR15","unstructured":"Bristol-Myers Squibb. A Phase 1\/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors. https:\/\/clinicaltrials.gov\/study\/NCT02472977 (2018)."},{"key":"76559_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1200\/JCO.2020.38.4_suppl.712","volume":"38","author":"D-Y Oh","year":"2020","unstructured":"Oh, D.-Y. et al. Phase Ib\/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). J. Clin. Oncol. 38, 712\u2013712 (2020).","journal-title":"J. Clin. Oncol."},{"key":"76559_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag023","volume":"31","author":"GA Manji","year":"2026","unstructured":"Manji, G. A. et al. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I\/IIb MORPHEUS-PDAC umbrella study.  Oncologist 31, oyag023 (2026).","journal-title":"Oncologist"},{"key":"76559_CR18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny, B. et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat. Med. 26, 878\u2013885 (2020).","journal-title":"Nat. Med."},{"key":"76559_CR19","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny, B. et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 Trial. Clin. Cancer Res. 27, 5020\u20135027 (2021).","journal-title":"Clin. Cancer Res."},{"key":"76559_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1037-z","volume":"14","author":"E Eriksson","year":"2016","unstructured":"Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A. & Ullenhag, G. Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the Teff\/Treg ratio in patients with pancreatic cancer. J. Transl. Med. 14, 282 (2016).","journal-title":"J. Transl. Med."},{"key":"76559_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","volume":"41","author":"A Obradovic","year":"2023","unstructured":"Obradovic, A. et al. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. Cancer Cell 41, 933\u2013949.e11 (2023).","journal-title":"Cancer Cell"},{"key":"76559_CR22","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-18-3281","volume":"25","author":"JA Eberle-Singh","year":"2019","unstructured":"Eberle-Singh, J. A. et al. Effective delivery of a microtubule polymerization inhibitor synergizes with standard regimens in models of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 25, 5548\u20135560 (2019).","journal-title":"Clin. Cancer Res."},{"key":"76559_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1101\/pdb.prot077834","volume":"2014","author":"SA Sastra","year":"2014","unstructured":"Sastra, S. A. & Olive, K. P. Acquisition of mouse tumor biopsies through abdominal laparotomy. Cold Spring Harb. Protoc. 2014, 47\u201356 (2014).","journal-title":"Cold Spring Harb. Protoc."},{"key":"76559_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","volume":"20","author":"SJ Fleming","year":"2023","unstructured":"Fleming, S. J. et al. Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender. Nat. Methods 20, 1323\u20131335 (2023).","journal-title":"Nat. Methods"},{"key":"76559_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"76559_CR26","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"76559_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","volume":"41","author":"T Gao","year":"2023","unstructured":"Gao, T. et al. Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes. Nat. Biotechnol. 41, 417\u2013426 (2023).","journal-title":"Nat. Biotechnol."},{"key":"76559_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36, 418\u2013430.e6 (2019).","journal-title":"Cancer Cell"},{"key":"76559_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"76559_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76559_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"76559_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080\u20131088 (2023).","journal-title":"Nature"},{"key":"76559_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.  Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"76559_CR34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"76559_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"76559_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"76559_CR37","first-page":"5363","volume":"32","author":"S Kan","year":"2012","unstructured":"Kan, S. et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 32, 5363\u20135369 (2012).","journal-title":"Anticancer Res."},{"key":"76559_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","volume":"16","author":"Y Homma","year":"2014","unstructured":"Homma, Y. et al. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin. Transl. Oncol. 16, 330\u2013335 (2014).","journal-title":"Clin. Transl. Oncol."},{"key":"76559_CR39","doi-asserted-by":"publisher","first-page":"19312","DOI":"10.18632\/oncotarget.8344","volume":"7","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. 5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation. Oncotarget 7, 19312\u201319326 (2016).","journal-title":"Oncotarget"},{"key":"76559_CR40","doi-asserted-by":"crossref","unstructured":"Bever, K. M. et al. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages. Oncoimmunology 14, 2543614 (2025).","DOI":"10.1080\/2162402X.2025.2543614"},{"key":"76559_CR41","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1007\/s11605-020-04697-1","volume":"24","author":"A Laura","year":"2020","unstructured":"Laura, A. et al. Is complete pathologic response in pancreatic cancer overestimated? a systematic review of prospective studies. J. Gastrointest. Surg. 24, 2336\u20132348 (2020).","journal-title":"J. Gastrointest. Surg."},{"key":"76559_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam, A. et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur. J. Cancer 108, 78\u201387 (2019).","journal-title":"Eur. J. Cancer"},{"key":"76559_CR43","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3892\/ol.2018.8296","volume":"15","author":"J Zhang","year":"2018","unstructured":"Zhang, J., Liu, C., Mo, X., Shi, H. & Li, S. Mechanisms by which CXCR4\/CXCL12 cause metastatic behavior in pancreatic cancer. Oncol. Lett. 15, 1771\u20131776 (2018).","journal-title":"Oncol. Lett."},{"key":"76559_CR44","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/sj.bjc.6605020","volume":"100","author":"R Mar\u00e9chal","year":"2009","unstructured":"Mar\u00e9chal, R. et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer 100, 1444\u20131451 (2009).","journal-title":"Br. J. Cancer"},{"key":"76559_CR45","first-page":"1159","volume":"16","author":"T Wehler","year":"2006","unstructured":"Wehler, T. et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol. Rep. 16, 1159\u20131164 (2006).","journal-title":"Oncol. Rep."},{"key":"76559_CR46","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/annonc\/mdr617","volume":"23","author":"JB Bachet","year":"2012","unstructured":"Bachet, J. B. et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann. Oncol. 23, 2327\u20132335 (2012).","journal-title":"Ann. Oncol."},{"key":"76559_CR47","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41588-022-01134-8","volume":"54","author":"WL Hwang","year":"2022","unstructured":"Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178\u20131191 (2022).","journal-title":"Nat. Genet."},{"key":"76559_CR48","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","volume":"8","author":"A Rousseau","year":"2023","unstructured":"Rousseau, A., Parisi, C. & Barlesi, F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open 8, 101184 (2023).","journal-title":"ESMO Open"},{"key":"76559_CR49","doi-asserted-by":"publisher","first-page":"e003776","DOI":"10.1136\/jitc-2021-003776","volume":"10","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski, P. et al. Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J. Immunother. Cancer 10, e003776 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"76559_CR50","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","volume":"9","author":"TW Kim","year":"2023","unstructured":"Kim, T. W. et al. Anti-TIGIT Antibody Tiragolumab alone or with Atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial. JAMA Oncol. 9, 1574\u20131582 (2023).","journal-title":"JAMA Oncol."},{"key":"76559_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/1535-7163.MCT-13-0324","volume":"13","author":"RB Slee","year":"2014","unstructured":"Slee, R. B. et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor, NMS-P715. Mol. Cancer Ther. 13, 307\u2013315 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"76559_CR52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-62703-287-2_13","volume":"980","author":"SA Sastra","year":"2013","unstructured":"Sastra, S. A. & Olive, K. P. Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol. Biol. 980, 249\u2013266 (2013).","journal-title":"Methods Mol. Biol."},{"key":"76559_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2326-6066.CIR-17-0360","volume":"6","author":"RD Gartrell","year":"2018","unstructured":"Gartrell, R. D. et al. Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol. Res. 6, 481\u2013493 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"76559_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41588-022-01268-9","volume":"55","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. Nat. Genet. 55, 19\u201325 (2023).","journal-title":"Nat. Genet."},{"key":"76559_CR55","doi-asserted-by":"publisher","unstructured":"Luthria, K. et al. Single-cell profiling of sarcomas from archival tissue reveals programs associated with resistance to immune checkpoint blockade. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2976 (2024).","DOI":"10.1158\/1078-0432.CCR-23-2976"},{"key":"76559_CR56","unstructured":"10x Genomics Cell Ranger v7.1.0."},{"key":"76559_CR57","unstructured":"What is the maximum number of cells that can be profiled? 10X Genomics https:\/\/kb.10xgenomics.com\/hc\/en-us\/articles\/360001378811-What-is-the-maximum-number-of-cells-that-can-be-profiled."},{"key":"76559_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"76559_CR59","doi-asserted-by":"crossref","unstructured":"Franz\u00e9n, O., Gan, L.-M. & Bj\u00f6rkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database 2019, baz046 (2019).","DOI":"10.1093\/database\/baz046"},{"key":"76559_CR60","unstructured":"broadinstitute\/infercnv: Inferring CNV from Single-Cell RNA-Seq. https:\/\/github.com\/broadinstitute\/infercnv."},{"key":"76559_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao, R. et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599\u2013608 (2021).","journal-title":"Nat. Biotechnol."},{"key":"76559_CR62","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.0308531101","volume":"101","author":"J-P Brunet","year":"2004","unstructured":"Brunet, J.-P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. USA 101, 4164\u20134169 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76559_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinform. 11, 367 (2010).","journal-title":"BMC Bioinform."},{"key":"76559_CR64","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"76559_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/2572105","volume":"28","author":"NJ Demerath","year":"1949","unstructured":"Demerath, N. J. The American Soldier: Volume I, Adjustment During Army Life. By S. A. Stouffer, E. A. Suchman, L. C. DeVinney, S. A. Star, R. M. Williams, Jr. Volume II, Combat and Its Aftermath. By S. A. Stouffer, A. A. Lumsdaine, M. H. Lumsdaine, R. M. Williams, Jr., M. B. Smith, I. L. Janis, S. A. Star, L. S. Cottrell, Jr. Princeton, New Jersey: Princeton University Press, 1949. Vol. I, 599 pp., Vol. II, 675 pp. $7.50 each; $13.50 together. Soc. Forces 28, 87\u201390 (1949).","journal-title":"Soc. Forces"},{"key":"76559_CR66","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng1861","volume":"38","author":"SL Carter","year":"2006","unstructured":"Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043\u20131048 (2006).","journal-title":"Nat. Genet."},{"key":"76559_CR67","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"76559_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1\u201348 (2015).","journal-title":"J. Stat. Softw."},{"key":"76559_CR69","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796\u20133798 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"76559_CR70","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"76559_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"76559_CR72","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76559-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:03:19Z","timestamp":1790726599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76559"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76559-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.A.M. received research support from BioLineRx Pharmaceuticals. In the last five years, G.A.M. has served as a consultant for or received honoraria from Exelixis, Roche\/Genentech, Ipsen, Cend Therapeutics, EnGeneIC, Pfizer, Revolution Medicines, and has received research funding to Columbia University from Merck (Inst), Roche\/Genentech (Inst), Plexxikon (Inst), Regeneron (Inst), BiolineRx (Inst), Arcus Biosciences, and has received travel accommodations from Roche\/Genentech, Exelixis, Celgene, Revolution Medicines, DAVA Oncology. G.A.M. has stock ownership interests in EnGeneIC. B.I. has a sponsored research agreement with Pharming Group. In the last five years, B.I. has served as a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson\/Janssen, Novartis, GSK, Eisai, AstraZeneca and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron, and Synthekine. B.I. is the scientific founder of Basima Therapeutics, Inc. K.P.O. has received research funding to Columbia University from Revolution Medicines. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10350"}}